左炔诺孕酮(Levonorgestrel) - 药物靶点：PR_在研适应症：月经紊乱，月经过多，避孕_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(-)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one、13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one、13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one

+ [52]

靶点

PR

作用方式

激动剂

作用机制

PR激动剂(孕激素受体激动剂)

治疗领域

泌尿生殖系统疾病其他疾病

在研适应症

月经紊乱月经过多避孕+ [1]

非在研适应症

痛经子宫内膜异位症出血+ [1]

原研机构

The Population Council, Inc.

在研机构

Medicines 360

Bayer AG

Foundation Consumer Healthcare LLC

+ [9]

非在研机构

Teva Branded Pharmaceutical Products R&D, Inc.Population Council's Center for Biomedical Research

The Population Council, Inc.

+ [2]

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1990-12-10),

避孕

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C21H28O2

InChIKeyWWYNJERNGUHSAO-XUDSTZEESA-N

CAS号797-63-7

关联

277

项与左炔诺孕酮相关的临床试验

NCT07222228

/ Not yet recruiting临床2期

A Phase 2b Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception

This is a multicenter, open-label, Phase 2b study to evaluate the efficacy and safety of 2 LB SQ injections administered at a 4-month (approximately 17 weeks) interval for female contraception.

开始日期2026-04-01

申办/合作机构

Premier Research

CTIS2025-523736-39-00

/ Not yet recruiting临床1期

Comparative Bioavailability of Levonorgestrel 52 mg Intrauterine System versus Mirena® in Healthy Pre-Menopausal, Non-Pregnant Female Participants.

开始日期2026-02-02

申办/合作机构

Laboratorios Leon Farma SA

NCT06904274

/ Recruiting临床3期

A Multi-center, Open Label, Randomized Parallel Group Study Evaluating the Proportion of Women With Complete Resolution of Nonatypical Endometrial Hyperplasia Treated With Mirena or Oral Medroxyprogesterone Acetate for 6 Months

Researchers are looking for a better way to treat women with nonatypical endometrial hyperplasia (NAEH).
Endometrial hyperplasia is a condition where the lining of the uterus (called the endometrium) becomes too thick. Nonatypical means that the condition is not cancerous. It is often caused by hormone imbalances in women. Symptoms can include abnormal vaginal bleeding or irregular periods. If this condition is not treated, then it may lead to cancer.
Currently, there are no approved treatments for NAEH and that is why there is still an unmet medical need.
The study treatment, Mirena (also known as BAY 865028), is already available as a type of birth control device. It is inserted into the uterus where it gradually releases progesterone.
In this study, researchers want to find out if Mirena works for women with NAEH. They believe it can help by keeping hormone levels balanced in the body.
The main purpose of this study is to show that uterine lining goes back to completely normal lining after treatment with Mirena and that its use is safe in this population.
For this, the researchers will compare the number of participants with benign endometrium after 6 months of treatment with Mirena or oral MPA.
The study participants will be randomly assigned into one of two treatment groups. The randomization will be done 2:1 ratio, meaning that for every two participants assigned to Mirena, one will be assigned to oral medroxyprogesterone acetate (MPA). Based on their group, participants will receive Mirena, which is inserted into the uterus at the start of the study, or they will take progestins once daily by mouth for 6 months.
Each participant will be in the study for around 10 months with up to 5 visits to the study clinic/site.
Participants will visit the study clinic:
* once before the treatment starts
* 3 times with a gap of 3 months between the visits during the treatment
* then 1 more time after the treatment ends
During the study, the doctors and their study team will:
* check participant's health by performing tests such as blood and urine tests
* perform vaginal ultrasound and hysteroscopy. Hysteroscopy is a minor surgical procedure where a thin camera will be inserted into the womb to check for any abnormality. Sampling of the endometrial lining (cells in the womb) will be done with a thin tube at the same time.
* take samples of womb (endometrial) lining
* ask the participants questions about how they are feeling and what adverse events they are having
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.

开始日期2025-11-24

申办/合作机构

Bayer AG

100 项与左炔诺孕酮相关的临床结果

登录后查看更多信息

100 项与左炔诺孕酮相关的转化医学

登录后查看更多信息

100 项与左炔诺孕酮相关的专利（医药）

登录后查看更多信息

6,740

项与左炔诺孕酮相关的文献（医药）

2026-01-01·INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Levonorgestrel-releasing intra-uterine device alone for managing early-stage endometrial cancer and endometrial hyperplasia with atypia in patients unfit for surgery: the ENDOIUD study

Article

作者: Raimondo, Diego ; Capozzi, Vito Andrea ; La Fera, Eleonora ; Dinoi, Giorgia ; Virdis, Giuseppe ; Raspagliesi, Francesco ; Arcieri, Martina ; Restaino, Stefano ; D'Antonio, Francesco ; Bogani, Giorgio ; Vizzielli, Giuseppe ; Petrillo, Marco ; Legge, Francesco ; Bruni, Simone ; Seracchioli, Renato ; Casadio, Paolo ; Dessole, Francesco ; Driul, Lorenza ; Di Donna, Mariano Catello ; Capobianco, Giampiero ; Berretta, Roberto ; Iodice, Raffaella ; Cucinella, Giuseppe ; Lucidi, Alessandro ; Fanfani, Francesco ; D'Angelo, Emanuela ; Chiantera, Vito ; Ceppi, Lorenzo ; Catena, Ursula ; Degano, Matilde

OBJECTIVE:

This study aimed to clarify the role of levonorgestrel-releasing intra-uterine device as a stand-alone therapy in managing patients with endometrial atypical hyperplasia/endometrial cancer who are not suitable for surgery, through the evaluation of cause-specific survival and the control of vaginal bleeding.

METHODS:

This is a retrospective, multi-center study conducted in 9 referral gynecologic centers in Italy. Data regarding the clinical and oncological outcomes of patients with endometrial atypical hyperplasia/endometrial cancer (International Federation of Gynecology and Obstetrics Stage I) were analyzed. Patients were judged unsuitable for surgery due to an American Society of Anesthesiologists score ≥3 and the presence of multiple severe co-morbidities and, therefore, triaged to receive levonorgestrel-releasing intra-uterine device alone.

RESULTS:

A total of 78 women were enrolled. Fifteen patients (19.2%) had a diagnosis of endometrial atypical hyperplasia, whereas the other 63 (80.8%) had endometrial cancer. The baseline hemoglobin levels averaged 11.6 (range; 6-16), increasing to 12.1 (range; 7.8-14.9) during follow-up after levonorgestrel-releasing intra-uterine device insertion (p = .003). No patient experienced any side effects, and bleeding control was rated as excellent in most patients. Median disease-free survival was 43 months (range; 5-120) and median overall survival was 45 months (range; 5-120).

CONCLUSIONS:

Levonorgestrel-releasing intra-uterine device alone is a safe and effective approach, showing no side effects, and a promising oncological outcome in women with early-stage endometrial atypical hyperplasia/endometrial cancer unfit for surgery. Future prospective studies are required to clarify how to select patient candidates for this therapy and how to predict response to levonorgestrel-releasing intra-uterine device.

2025-12-31·INTERNATIONAL JOURNAL OF HYPERTHERMIA

High-intensity focused ultrasound combined with hysteroscopic insertion of levonorgestrel-releasing intrauterine system for intrinsic adenomyosis: a retrospective observational study

Article

作者: Ding, Kun ; Zhao, Lei ; Zhao, Shuping ; Sang, Changmei ; Kang, Yanjun

OBJECTIVE:

To retrospectively analyze the safety and efficacy of high-intensity focused ultrasound (HIFU) combined with hysteroscopic insertion of Levonorgestrel-Releasing Intrauterine System the treatment of intrinsic adenomyosis.

METHODS:

A total of 30 patients with intrinsic adenomyosis were enrolled. All patients initially underwent HIFU treatment, followed by hysteroscopic surgery to remove the remaining unabsorbed necrotic tissue and simultaneously insert the levonorgestrel-releasing intrauterine system (LNG-IUS) for long-term management of adenomyosis. The treatment results, adverse events, and 2-year follow-up data were analyzed statistically.

RESULT:

All 30 patients successfully completed the treatment without serious complications, and achieved remarkable symptom improvement. The VAS score of dysmenorrhea and MSF score of menorrhagia both decreased significantly (p < 0.05). Uterine volume decreased significantly after treatment (p < 0.05). The proportion of patients with dysmenorrhea and menorrhagia who experienced significant symptom relief was 86.7% and 93.3%, and the clinical efficacy rates were 93.3% and 96.7% respectively, with no recurrent cases. LNG-IUS was inserted during hysteroscopic surgery in 30 patients. Up to the time of submission, no significant symptom recurrence and the LNG-IUS displacement rate is 3.3%.

CONCLUSION:

Combination of HIFU and hysteroscopic insertion of Levonorgestrel-Releasing Intrauterine System is an effective and recommended therapeutic strategy for treating intrinsic adenomyosis.

2025-12-31·ANNALS OF MEDICINE

Rationale and design of the GLADE study: a randomized, multicenter, double-blind, placebo-controlled trial evaluating the safety and efficacy of gestrinone subdermal bioabsorbable pellet in endometriosis-related pelvic pain

Article

作者: Agati, Leandro Barile ; Silva Filho, Agnaldo ; Lopes, Francisco ; Westphalen, Nathalia ; Comin, Ana ; Ramacciotti, Eduardo ; Bezerra Neto, Eduardo José ; Schor, Eduardo ; Berger, Charles ; Ribeiro, Camilla Moreira ; Socca, Eduardo Augusto Rabelo ; Malavasi, André ; Oliveira, Taís Helena de ; Caldas, Polyana Raposo ; Komar, Daniele ; Vieira, Francisleny

BACKGROUND:

Pelvic pain secondary to endometriosis is a disabling condition. There are multiple treatments available, with variable endpoints. No prospective controlled studies were carried out evaluating subdermal pellets of gestrinone in this population.

METHODS:

One hundred participants with documented deep infiltrative endometriosis who underwent surgery without satisfactory response will be randomly assigned (1:1) to either gestrinone 85 mg subdermal bioabsorbable pellets or placebo. Both arms will receive levonorgestrel-releasing intrauterine system (LNG-IUS 12). The treatment duration will be 6 months, with baseline, 3 months and 6 months clinical visits. The primary endpoint is a combination of serious adverse events (SAEs) accumulated within 6 months of insertion of the gestrinone or placebo pellet and collected through spontaneous reports and clinical findings. They include death, threat or risk to life, need for hospitalization, prolongation of pre-existing hospitalization, permanent disability or damage, congenital anomaly; or significant medical occurrences such as venous thromboembolism. The primary safety outcome will be the percentage of patients who do not experience SAEs 6 months after randomization. Androgenization, changes in laboratory exams and in pelvic pain intensity as well as quality of life (SF-36 and EHP-30 questionnaires) will be further evaluated. Daily data on uterine bleeding patterns and the use of pain relief medication will be remotely collected using an App. Pharmacokinetics profile of gestrinone pellet will be characterized.

CONCLUSION:

This is the first multicenter randomized controlled trial to evaluate the safety, tolerability and pharmacokinetics profile of subdermal gestrinone pellets and might inform clinical practice for treating these patients.

ADMINISTRATIVE INFORMATION:

GLADE trial is registered at ClinicalTrials.gov (NCT05570786). This is an investigator-initiated research supported by Biòs Farmacêutica.

253

项与左炔诺孕酮相关的新闻（医药）

2025-12-05

·拜耳中国

拜耳启动曼月乐®治疗子宫内膜增生不伴非典型性（NAEH）的Ⅲ期临床研究

拜耳长效可逆宫内装置曼月乐®（左炔孕诺酮宫内释放系统）丰富临床开发项目继续扩展；中国研究中心与全球同步开展该项临床研究；子宫内膜增生不伴非典型性（NAEH）是一种良性子宫内膜增厚性病变；根据人群差异，NAEH的年新发病例数在每10万名女性中约为121至270例1,2,3，目前尚无获批的NAEH治疗方案；曼月乐®已在全球超过120个国家或地区上市，获批适应症（因国家或地区而异）包括避孕、治疗月经过多、更年期雌激素治疗期间的子宫内膜保护，以及缓解痛经；拜耳不断加强在女性健康领域的领先优势，积极探索并推动创新，回应未被满足的医疗需求。近日，拜耳宣布启动曼月乐®（左炔诺孕酮宫内释放系统）Ⅲ期SUNFLOWER临床研究，评估其在治疗子宫内膜增生不伴非典型性（NAEH）女性患者中的疗效与安全性，中国研究中心与全球同步开展该项临床研究。 NAEH是由于雌激素与孕激素水平失衡引起的子宫内膜异常增厚。之所以被归类为“不伴非典型性”是因为子宫内膜细胞未显示癌变迹象。患者可能无症状，也可能出现月经过多、异常出血或绝经后出血。如不及时治疗，该病可能进展为子宫内膜非典型增生，甚至子宫内膜癌。NAEH的年发病率因地理位置、年龄及绝经状态不同，每10万名女性约为121至270例，目前尚无获批的治疗方案。 Christian Rommel博士拜耳处方药事业部全球研发负责人 “作为全球女性健康领域的领导者，拜耳始终致力于推动科学进步，聚焦创新方案以满足女性未被满足的医疗需求。通过这项新的Ⅲ期临床研究，我们进一步扩展宫内释放系统的临床开发项目，期待为NAEH患者提供有效的治疗选择。” 向上滑动阅览关于SUNFLOWER研究 SUNFLOWER Ⅲ期临床研究将比较左炔诺孕酮宫内释放系统与口服孕激素在治疗NAEH中的疗效，计划在3个国家约90个临床中心招募207名患者，预计历时约1.5年完成。既往研究已经发现左炔诺孕酮宫内释放系统在该类患者中反应良好4,5,6，其所含激素直接在子宫内释放，并发挥作用。SUNFLOWER研究旨在通过临床研究进一步验证这一治疗方案的有效性。关于曼月乐® 曼月乐®是一种含有52mg合成左炔诺孕酮的“T”字形装置，置入子宫后可持续释放少量左炔诺孕酮，直接作用于子宫内膜。作为一种长效可逆避孕方法，曼月乐®可在女性需要时由医疗专业人员随时取出。目前，曼月乐®已在全球超过120个国家或地区上市，获批适应症（因国家或地区而异）包括避孕、治疗特发性月经过多或月经过多（HMB）、在更年期雌激素治疗期间提供子宫内膜保护，以及缓解痛经。关于拜耳女性健康女性健康是拜耳的核心领域。作为全球女性健康的领导者，拜耳长期致力于以科学创新改善生活，推动创新治疗方案的研发。公司提供多种有效的短效与长效避孕方法，以及更年期管理和妇科疾病治疗方案。与此同时，拜耳专注于开发创新解决方案，以满足全球女性未被满足的医疗需求，并拓展治疗选择，例如更年期管理。此外，拜耳计划到2030年，每年为低收入和中等收入国家的1亿女性提供避孕服务，公司将通过资助多方合作的援助项目，支持能力建设，并确保供应价格可负担的现代避孕药具。这一举措是拜耳自2020年起实施的全面可持续发展战略与承诺的重要组成部分，并与联合国可持续发展目标保持一致。关于拜耳拜耳作为一家跨国企业，在生命科学领域的医疗健康与农业方面具有核心竞争力。秉承“共享健康，消除饥饿”的使命，公司致力于通过产品和服务，帮助人们克服全球人口不断增长和老龄化带来的重大挑战，造福人类和地球繁荣发展。拜耳致力于推动可持续发展并对业务产生积极影响。同时，集团还通过科技创新和业务增长来提升盈利能力并创造价值。在全球，拜耳品牌代表着可信、可靠及优质。在2024财年，拜耳的员工人数约为93,000名，销售额为466亿欧元。不计特殊项目的研究开发投入为62亿欧元。更多信息请见www.bayer.com。前瞻性声明本新闻稿包括拜耳集团管理层基于当前设想和预测所作的前瞻性声明。各种已知和未知的风险、不确定性和其它因素均可能导致公司未来的实际运营结果、财务状况、发展或业绩与上述前瞻性表述中所作出的估计产生重大差异。这些因素包括在拜耳官方网站http://www.bayer.com/上公开的拜耳各项报告。本公司没有责任更新这些前瞻性声明或使其符合未来发生的事件或发展。参考文献 Ring, K.L., A.M. Mills, and S.C. Modesitt, Endometrial Hyperplasia. Obstet Gynecol, 2022. 140(6): p. 1061-1075. Reed SD, Newton KM, Clinton WL, Epplein M, Garcia R, Allison K, Voigt LF, Weiss NS. Incidence of endometrial hyperplasia. Am J Obstet Gynecol. 2009 Jun;200(6):678.e1-6. doi: 10.1016/j.ajog.2009.02.032. Epub 2009 Apr 23. PMID: 19393600; PMCID: PMC2692753. Petersdorf K, Groettrup-Wolfers E, Overton PM, Seitz C, Schulze-Rath R. Endometrial hyperplasia in pre-menopausal women: A systematic review of incidence, prevalence, and risk factors. Eur J Obstet Gynecol Reprod Biol. 2022 Apr;271:158-171. doi: 10.1016/j.ejogrb.2022.02.015. Epub 2022 Feb 17. PMID: 35217456. Abu Hashim H, Ghayaty E, El Rakhawy M. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol. 2015 Oct;213(4):469-78. doi: 10.1016/j.ajog.2015.03.037. Epub 2015 Mar 19. PMID: 25797236. Mittermeier T, Farrant C, Wise MR. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database Syst Rev. 2020 Sep 6;9(9):CD012658. doi: 10.1002/14651858.CD012658.pub2. PMID: 32909630; PMCID: PMC8200645. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010 Dec;203(6):547.e1-10. doi: 10.1016/j.ajog.2010.07.037. PMID: 20934679

2025-12-04

·IVD资讯

避孕药具，要涨价了！

来源：闪电新闻、医药代表 2026年1月1日起，销售避孕药品和用具将依法征收增值税，不再享受免征增值税的优惠政策。目前施行的《中华人民共和国增值税暂行条例》第十五条规定，避孕药品和用具免征增值税；而2026年1月1日起施行的《中华人民共和国增值税法》第二十四条免征增值税的项目中，则不再设有“避孕药品和用具”这一项。免征增值税政策的取消，将对避孕药品和用具的生产、销售企业产生直接影响，企业需要重新评估成本结构，调整定价策略，并可能面临市场竞争加剧的挑战。随着增值税的征收，避孕药品和用具的市场价格可能会上涨，从而增加消费者的购买成本。 2026年1月1日起，销售避孕药品和用具将需按照增值税法规要求开具相应的增值税专用发票或普通发票。有药企已经开始调价。一份某药企《关于左炔诺孕酮肠溶片价格变更沟通函》在业界流传。内容显示，为积极响应国家政策，并基于当前市场环境与公司战略发展需要，该药企经审慎研究，决定对左炔诺孕酮肠溶片的价格体系进行相应变更。大家抓紧生孩子吧声明：本微信注明来源的稿件均为转载，仅用于分享，不代表平台立场，如涉及版权等问题，请尽快联系我们，我们第一时间更正。

2025-12-03

·医药代表

避孕药涨价，开始了？！

自上月底以来，一直传闻避孕类产品要涨价，现在有厂家消息出来了。本周，一份某药企《关于左炔诺孕酮肠溶片价格变更沟通函》在业界流传，内容显示，为积极响应国家政策，并基于当前市场环境与公司战略发展需要，该药企经审慎研究，决定对左炔诺孕酮肠溶片的价格体系进行相应变更。从价格列表来看，该司生产的左炔诺孕酮肠溶片，规格是 1.5mg*1 片，终端客户购进价格为 13.90 元，建议零售价格为 39.80 元。 MRCLUB 的小伙伴们基本都是学医学药的，大家知道，左炔诺孕酮肠溶片是一种孕激素类紧急避孕药，其主要成分为左炔诺孕酮，通过抑制排卵、阻止受精卵着床等方式发挥作用，所以，这款药品在生活中，主要用于无防护性生活或避孕失败后的紧急避孕。该药企表示，调价是根据国家将于 2026 年 1 月 1 日正式施行的《增值税法》相关规定，避孕药品的增值税政策将进行调整。目前，避孕药品和用具的税务政策是按照《增值税暂行条例》，在《增值税暂行条例》中，第十五条列举了免征增值税的项目，其中包括避孕药品和用具。该《暂行条例》于 1993 年增值税法暂行条例首次公布时，就将避孕药品和用具列入了免税项目中，此后几次修订均保留，当时的考虑是降低避孕成本，控制人口过快增长。为了落实税收法定原则，增值税从国务院暂行条例上升为法律，新的《增值税法》于 2024 年 12 月 25 日已经通过，将于 2026 年 1 月 1 日起施行，目前在国家税务总局网站可以查询，可以看到，将施行的《增值税法》中的免征增值税项目，已经没有了“避孕药品和用具”这一项。据第一财经报道，中国政法大学财税法研究中心主任施正文告诉记者，因为当前我国人口政策已经发生了很大变化，避孕药品和用具应当适用与其他普通药品和用具相同的税收待遇。上海交通大学财税法研究中心副主任王桦宇也认为，这主要是中国人口政策调整，目前鼓励生育。因此，这一税收优惠政策也随之调整。大伙儿不妨预测下，接下来的一个月，会有更多的药企对相关药品进行调价吗？近日热点阅读：老字号药企，副总裁辞职这起美国药企收购泡汤了 18家药企获得LGBTQ+组织“黄金认证” 国家药监局原副局长陈时飞被公诉一药企四高管被罚！雅培官宣，超千亿元重磅收购 170万年薪，威高骨科总经理辞职 1400万！国家医保局曝光回扣大案 3家药企，取消集采中选资格实施医药代表驻地双轨制默沙东韩婷，加入强生护士未经指示X光检查被判有罪安斯泰来中国“焕新”记国家医保局再发药剂科主任受贿案参天中国区人事巨震，总部接管国内药企，又有两人被查国药控股，更换董事长国药系药企，又一副总辞任金肖东辞任辉瑞刚刚，A司释放大量信息！一药企公布自查结果，补税1600余万又一药品被停采默克高层调整！罗杰仁重返中国履新 BMS中国血液团队全国热招岗位赛诺菲诚聘血液肿瘤医药精英拜耳中国最新全国职位最新药企内部招聘（11月29日更新） #跨国药企在进博会医药代表伴您成长！

并购高管变更

100 项与左炔诺孕酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00950	左炔诺孕酮	G03AC03 G03AD01	DB00367

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
月经紊乱	日本	Bayer Yakuhin Ltd.	2014-11-18
月经过多	美国	Bayer HealthCare Pharmaceuticals, Inc.	2000-12-06
避孕	美国	The Population Council, Inc.	1990-12-10
避孕	美国	Wyeth Pharmaceuticals LLC	1990-12-10

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
子宫内膜增生	临床3期	美国	Bayer AG	2025-11-24
子宫内膜增生	临床3期	中国	Bayer AG	2025-11-24
子宫内膜增生	临床3期	加拿大	Bayer AG	2025-11-24
痛经	临床3期	美国	Teva Branded Pharmaceutical Products R&D, Inc.	2005-01-01
出血	临床3期	比利时	Bayer AG	2000-05-01
出血	临床3期	芬兰	Bayer AG	2000-05-01
出血	临床3期	荷兰	Bayer AG	2000-05-01
出血	临床3期	英国	Bayer AG	2000-05-01
绝经期综合征	临床3期	比利时	Bayer AG	2000-05-01
绝经期综合征	临床3期	芬兰	Bayer AG	2000-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed \| NEWS 人工标引	N/A	脑膜瘤	-	desogestrel 75µg	壓夢憲醖衊膚觸壓淵鏇(簾鹽廠製窪遞淵蓋繭襯) = 鏇鬱顧鹽壓遞衊醖獵觸積鑰襯襯築願鹹夢襯選 (鹹窪齋淵壓築衊壓膚襯, 1.10 ~ 1.42) 更多	积极	2025-06-11
				levonorgestrel 30 µglevonorgestrel 30 µg	壓夢憲醖衊膚觸壓淵鏇(簾鹽廠製窪遞淵蓋繭襯) = 築廠膚襯獵夢廠選範構積鑰襯襯築願鹹夢襯選 (鹹窪齋淵壓築衊壓膚襯, 0.87 ~ 2.40) 更多
NCT04678817 (Pubmed \| Contraception)	N/A	避孕	160	Etonogestrel implant	範鏇選糧餘憲顧艱築簾(壓築獵鑰遞鏇鑰鹽淵餘) = 窪簾顧襯鏇蓋獵餘製鏇製顧積獵觸範繭網構範 (鏇範淵願糧壓襯鬱鹹淵 )	积极	2025-05-01
NCT05492487 (not provided, Pubmed \| J Assist Reprod Genet)	临床2期	子宫内膜样上皮内瘤变	-	Megestrol Acetate	襯獵鹽鬱衊繭網獵齋簾(網齋獵餘襯襯築獵糧襯) = 醖餘積蓋顧鑰網蓋製觸選網齋衊醖壓齋積憲窪 (獵鹽艱範淵蓋壓壓遞範 ) 更多	积极	2024-08-31
				Levonorgestrel-Intrauterine System	襯獵鹽鬱衊繭網獵齋簾(網齋獵餘襯襯築獵糧襯) = 醖構鑰鏇鏇簾製鑰鑰選選網齋衊醖壓齋積憲窪 (獵鹽艱範淵蓋壓壓遞範 ) 更多
NCT00995150 (Not provided, CTgov)	临床3期	避孕	1,910	Mirena (Mirena)	糧淵願顧構壓鑰簾廠獵 = 顧獵願鑰遞膚憲壓簾願網簾範齋窪齋獵製遞築 (膚網淵鏇網選選網醖廠, 壓衊壓願構願願築衊廠 ~ 鬱鏇憲選廠範獵網鹹鏇) 更多	-	2024-08-14
				LNG20 (LNG20 (16-35 Year Olds))	窪積鏇鹹膚淵繭鹽衊膚 = 構網顧膚廠鏇鏇選簾壓簾遞壓網遞餘膚積鏇窪 (醖襯醖淵觸淵築鹽壓鏇, 淵繭壓鹽願構糧鹹衊餘 ~ 鑰繭範鬱衊膚積繭廠構) 更多
NCT03614494 (CTgov)	临床2/3期	避孕	860	Levonorgestrel+Piroxicam 40 mg (Piroxicam)	襯顧壓鬱鑰憲構窪製廠 = 窪築鹹簾蓋齋選築積鏇廠窪淵廠積膚鑰膚願鏇 (淵選遞製簾鹹齋網艱繭, 觸築顧築鏇築廠蓋餘壓 ~ 廠窪築觸顧範範壓餘顧) 更多	-	2024-05-06
				Levonorgestrel (Placebo)	襯顧壓鬱鑰憲構窪製廠 = 築壓鏇獵遞範鏇鑰糧夢廠窪淵廠積膚鑰膚願鏇 (淵選遞製簾鹹齋網艱繭, 積衊襯壓襯鹹鏇餘膚選 ~ 願顧構積積廠製餘衊壓) 更多
NCT02550067 (ECHO, Pubmed \| BMC Womens Health) 人工标引	N/A	避孕	398	Depot medroxyprogesterone acetate (DMPA-IM)	艱壓憲醖鹹餘網願齋齋(鹹鬱繭選選鑰淵構遞積) = 襯築糧鬱鬱艱製繭鏇蓋襯願膚願鏇範憲繭願範 (鑰衊範齋鏇簾壓壓窪艱 ) 更多	积极	2024-03-08
				copper intrauterine device	艱壓憲醖鹹餘網願齋齋(鹹鬱繭選選鑰淵構遞積) = 選範構膚觸範遞鏇窪膚襯願膚願鏇範憲繭願範 (鑰衊範齋鏇簾壓壓窪艱 ) 更多
NCT04678817 (Pubmed \| Contraception) 人工标引	N/A	避孕	153	Oral levonorgestrelwith same-day etonogestrel implant	襯鹽構簾選廠襯鹽壓鑰(齋築醖築選膚糧選齋餘) = 糧憲餘願鹽壓願鏇糧廠鏇壓衊簾壓鬱壓鹹蓋窪 (繭衊醖窪構壓糧構壓願, 0.23 ~ 5.19) 更多	积极	2023-11-25
FDA 人工标引	N/A	月经过多	105	LILETTA	齋憲糧鏇選夢築餘窪壓(觸壓積積觸齋餘鏇襯製) = 蓋餘艱獵選襯顧淵積餘簾淵夢壓壓選鹹網廠鏇 (壓廠積繭衊築構鏇蓋衊, 71 ~ 88) 更多	积极	2023-06-29
NCT02863445 (EC-Obesity, CTgov)	临床4期	肥胖	70	Levonorgestrel-based emergency contraception 1.5 mg (LNG-ECx1)	憲餘蓋廠範糧獵顧壓壓 = 鬱網淵壓糧膚顧齋製構憲艱蓋獵簾憲鏇簾憲窪 (遞築構鹽製膚蓋觸夢廠, 網築淵鹹網糧顧壓淵選 ~ 選獵觸觸網獵觸顧構積) 更多	-	2023-06-15
				Levonorgestrel-based emergency contraception 3.0mg (LNG-ECx2)	憲餘蓋廠範糧獵顧壓壓 = 鏇艱觸壓範構鹹鬱廠淵憲艱蓋獵簾憲鏇簾憲窪 (遞築構鹽製膚蓋觸夢廠, 積鏇遞積醖憲廠願廠艱 ~ 窪蓋築糧醖艱淵繭顧築) 更多
NCT03642210 (Pubmed \| Obstet Gynecol)	临床3期	月经过多	105	Levonorgestrel 52-mg Intrauterine Device	選遞鑰醖構廠齋製艱觸(艱遞積憲憲簾築壓齋艱) = n=6 [5.7%] 鹽膚鬱壓廠範襯膚簾襯 (範積齋糧網鏇選襯淵壓 ) 更多	-	2023-05-01